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Background: Jugular venous distension, reflecting raised right atrial pressure (RAP), is a 
classical sign of congestive heart failure (CHF), but its clinical assessment can be difficult. 
 
Methods: RAP was measured non-invasively using near-infrared spectroscopy (NIRS) over 
the external jugular vein (Venus 1000, Mespere LifeSciences, Canada) in ambulatory patients 
with CHF enrolled in the “Studies Investigating Co-morbidities Aggravating Heart Failure” 
(SICA-HF) programme. 
 
Results: Comparing 243 patients with CHF (mean age 71 years; mean left ventricular ejection 
fraction (LVEF) 45%, median NT-proBNP 788 ng/l) to 49 controls (NTproBNP < 125 ng/l), 
RAP was 7 (IQR: 4-11) versus 4 (IQR: 3-8) mmHg, p<0.001. Those with RAP >10 mmHg 
(N=75) were older, had more severe clinical congestion and renal dysfunction, higher plasma 
NTproBNP, larger left atrial volume, higher systolic pulmonary pressure and were more often 
in atrial fibrillation but their LVEF was similar to patients with lower RAP.  
 
During a median FU of 595 (IQR: 492-714) days, 49 patients (20%) died or were hospitalized 
for worsening CHF. Compared to patients with RAP <5 mmHg, those with RAP >10 mmHg 
had a greater risk of an event (HR 2.38, 95% CI: 1.19-4.75, p=0.014). RAP measured by NIRS 
predicted outcome, competing with NT-proBNP in multivariable models.   
 
Conclusions: Measuring RAP using NIRS identifies ambulatory patients with CHF who have 
more severe congestion and a worse outcome. The device might be a useful objective method 
of monitoring RAP, especially for those inexperienced in eliciting physical signs or when 
measurement of natriuretic peptides is not immediately available. 
Key words: heart failure, Near-Infrared Spectroscopy, right atrial pressure, prognosis. 
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Introduction 
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An increased jugular venous pressure (JVP), reflecting raised right atrial pressure (RAP) is not 
only a classical sign of congestive heart failure (HF) but also a powerful predictor of an adverse 
outcome. (1) 
 
When the JVP is raised, expert doctors are likely to make a correct diagnosis of congestion and 
impaired haemodynamics (2); but assessing the JVP is challenging, and many clinicians are 
neither familiar with its measurement nor skilled in its interpretation. (3,4) Measurement of 
inferior vena cava (IVC) or internal jugular vein diameter (JVD) by ultrasound provide an 
indirect estimate of RAP, and identify with more precision patients with HF who are congested 
and at high risk of adverse events (5-8); however, these ultrasonic methods require specific 
probes and trained personnel.  
 
Although the discovery of near-infrared energy dates to the beginning of the 19th century (9), 
it is only recently that interest in near-infrared spectroscopy (NIRS) has grown as a tool for 
medical research that might have a wide range of clinical applications (10-12). 
 
NIRS of the external jugular vein allows easy, quick, and non-invasive estimation of RAP. We 
investigated whether NIRS-derived RAP readings are clinically relevant, by relating them to 
other clinical, biochemical and ultrasound indices of cardiac dysfunction and congestion, and 
by assessing their prognostic value in out-patients with HF.  
  
 
Methods 
NIRS and outcome  Pellicori et al 130217_V2 
 
   Page 5 of 21 
 
Study Population  
Between April 2013 and April 2014, consecutive control subjects and patients with HF were 
enrolled in Kingston-Upon-Hull, UK, for the Studies Investigating Co-morbidities 
Aggravating Heart Failure (SICA-HF, ClinicalTrials.gov Identifier: NCT01872299) (13). 
SICA-HF is an international observational study of the prevalence, incidence and impact of 
key co-morbidities in out-patients with a clinical diagnosis of HF. For the purpose of this 
analysis, we considered patients to have cardiac dysfunction as the likely cause of HF 
symptoms if they had LVEF <50% or abnormal NT-proBNP (>125 ng/L) (14). Patients with 
end-stage renal failure or on renal dialysis, an alternative cause for raised NT-proBNP, were 
not enrolled in the study.  
 
Controls were subjects aged >60 years who had no history of HF who were recruited to the 
SICA-HF study by invitation from primary care practice lists, the majority of whom had 
hypertension or type-2 diabetes. All control subjects had to have normal left ventricular 
function on echocardiography and a plasma NTproBNP <125 ng/l.  
 
Patients were managed according to contemporary guidelines and assessed after optimisation 
of their medical therapy. Patients provided a detailed clinical history and blood tests 
(including haematology, biochemistry profile and NT-proBNP) and had an electrocardiogram 
and echocardiogram on the same day. Patients in atrial fibrillation or atrial flutter were 
grouped as “AF”.  
 
Patients were followed up until 30th June 2015. The primary outcome of interest was a 
composite of HF hospitalization or all-cause mortality. Our hospital is the only one in the 
region offering acute medical services. We have access to all primary and secondary care 
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records. Outcome is censored at the point of last medical contact in primary or secondary care. 
Data regarding deaths and hospitalisations were collected from the hospital’s electronic 
systems, supplemented by information from patients, discharge letters and their family doctors. 
Hospitalisations were considered to be HF-related if the discharge letter suggested HF as a key 
reason for admission. All data regarding admissions and deaths were entered into a dedicated 
online database, and were adjudicated at regular intervals by different researchers blind to any 
other measurement collected at the time of the clinical visit.  
 
The investigation conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent.  
 
Clinical examination 
Clinical examinations were performed by an experienced doctor (PP) before 
echocardiography and NIRS evaluation. A clinical congestion score was applied, based on 
lung auscultation (normal, presence of basal, mid zone or diffuse crackles), JVP (not visible, 
raised 1-4 cm, raised to earlobe), peripheral oedema (none, ankles, below or above knees) 
and liver examination (not palpable, palpable) with one point attributed for each degree of 
severity. Patients with a score of three or more out of a possible score of nine were defined as 
being congested (15).  
 
NIRS measurements 
Following clinical examination and before echocardiography, with the patient reclining and 
head and neck elevated at 45°, RAP was measured using NIRS (Venus 1000, Mespere 
LifeSciences, Canada, Figure 1), a portable device that includes adhesive patches connected 
to a reading electrode placed over the external jugular vein on the right side of the neck and a 
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reference point aligned with the right atrium (the fourth intercostal space at the mid-antero-
posterior diameter of the chest wall). NIRS works by projecting near-infrared light into the 
neck tissue adjacent to the external jugular vein to detect and analyse reflected light. As the 
absorption of near-infrared light is mainly by haemoglobin, variations in the amplitude of 
reflected light are related to pulsations in the superficial external jugular vein. Once the 
jugular venous pulse is detected, pressure is measured compared to a zero-reference, usually 
the 4th intercostal space in the mid-antero-posterior diameter of the chest wall.  If the height 
of the JVP is above or below the reading electrode, the device prompts adjustment of the 
slope at which the patient is lying. Once stable waveforms and readings are obtained, the 
device records RAP (in mmHg). It takes about two minutes to conduct the test.  
 
Echocardiographic measurements 
Echocardiography was performed by a single operator (AB) using a Vivid Seven (GE Health 
care, UK) system operating at 1.7-3.4MHz. Doppler tracings and two-dimensional images 
were obtained from parasternal long- and short-axis, apical and subcostal views. 
Echocardiograms were stored and reviewed by the same operator blinded to other patient 
details using an EchoPAC station (GE Health care, UK). LVEF was measured using 
Simpson’s biplane method. LA volume was measured in the four-chamber view and indexed 
to body surface area (LAVI). Tricuspid annular plane systolic excursion (TAPSE) was used 
to assess right ventricular (RV) systolic function. The maximum trans-tricuspid systolic 
gradient was also measured by echocardiography (based on the modified Bernoulli equation, 
ΔP = Max TR velocity2 x 4). With the patient in the supine position, the maximum inferior 
vena cava (IVC) diameter during the respiratory cycle was measured between one and three 
centimeters before merger with the right atrium.  
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Jugular vein ultrasound assessment 
We have previously reported the method and reproducibility for measuring JVD ratio. (5,6) 
With the patient reclining and head and neck elevated at 45°, a linear high-frequency probe (10 
MHz) was placed on the left side of the neck below the angle of the jaw and moved inferiorly 
toward the angle of Louis until the left internal JV was identified.  Internal JV diameter and its 
changes were then measured continuously by M-mode or in the 2-dimensional frame at rest 
(expiratory phase), during a Valsalva manoeuvre (performed by forceful expiration against a 
closed glottis) and, finally, during deep inspiration by AB. The ratio between maximum JV 
diameter during Valsalva and diameter at rest was calculated (JVD ratio).    
 
Statistical methods 
Categorical data are presented as percentages; normally distributed continuous data as mean 
+ standard deviation (SD) and non-normally distributed variables as median and interquartile 
range (IQR). 
 
Patients with HF were grouped by normal (<5 mmHg), borderline (6-9 mmHg) or raised (>10 
mmHg) RAP. One-way ANOVA and Kruskal-Wallis tests were used to compare continuous 
variables between groups depending on the normality of the distribution, and the chi-squared 
test was used for categorical variables.  
 
Different multivariable models were tested using a limited number of variables to prevent 
statistical overfitting. In Model A, we chose, prospectively, five candidate variables of 
interest (age, NYHA class, creatinine, LVEF and log [NTproBNP]) in addition to RAP; for 
Model B (biochemical), we selected the biochemical variables that were most strongly 
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associated with prognosis in univariable analysis, in addition to age, log[NTproBNP] and 
RAP; for model C (echocardiography) we selected echocardiographic variables strongly 
associated with outcome in univariable analysis, including and excluding IVC diameter, in 
addition to age and RAP.    
 
Treatment variables were not included in models as these might be confounded by indication 
and might vary over time. We did not include mitral and tricuspid regurgitation because their 
estimation was semi-quantitative and because we included patients with AF, which might 
make the interpretation of valvular regurgitation difficult. Forward and backward procedures 
were used to determine which variables independently predicted the primary composite 
outcome. Assumptions of the models were tested, such as multicolinearity and proportional 
hazards. 
 
Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. 
All the analyses were performed using SPSS v.22 and Stata software. A 2-sided p-value < 
0.05 was considered statistically significant. 
 
 
Results 
Patient characteristics 
The mean age of patients with CHF (n=243, table 1) was 71 (±10) years, 36% were women, 
58% had IHD and 28% had AF.  Mean LVEF was 45 (±13)% and median plasma 
NTproBNP was 788 [280 –1481] ng/l. Approximately 80% of patients were treated with 
beta-blockers and ACE-inhibitors and 63% were taking loop diuretics.  
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Amongst controls (n = 49), 84% had diabetes (DM), 69% had hypertension (HTN) and 16% 
IHD. Their mean age was 72 (±8) years, 49% were men; mean LVEF was 60 (±5)% and 
median NT-proBNP 72 (45-104) ng/l. 
 
 
Reproducibility of Measurements of right atrial pressure by NIRS 
RAP by NIRS was measured separately by two operators blind to each other’s results in 20 
patients. The reproducibility of RAP measurements was tested using the Bland-Altman 
method. Inter-operator reproducibility of RAP was good (Figure 1 supplementary; mean 
difference for RAP (±SD): 0.3 (±1.8) mmHg; upper and lower limit of agreement: 3.8; -3.2 
mmHg, with no value outside limits of agreement). Moving the reference point from the 4th 
to 3rd intercostal space lead to slightly lower readings (mean 3.4 (4.1) mmHg vs 4.8 (3.6) 
mmHg, p=0.001), but moving the reference point from the 4th to 5th did not significantly 
affect results (4.7 (4.4) mmHg vs 4.8 (3.6) mmHg, p=0.68; figure 2 and 3 supplementary for 
Bland-Altman plots). The distribution of RAP measured by NIRS in patients with HF and 
controls is shown in a supplementary figure (4).  
 
 
RAP by NIRS, clinical and echocardiographic findings  
RAP by NIRS could be obtained in all patients; RAP was higher in patients with HF than 
controls. Amongst patients with CHF, those with RAP >10 mmHg were older, were more 
symptomatic, had worse renal function and lower haemoglobin, were more likely to have AF 
and a clinically raised JVP, and had more clinical and biochemical (NTproBNP) signs of 
congestion (table 1). They had larger left ventricular and atrial volumes, worse right 
ventricular systolic function, higher systolic pulmonary pressure, greater IVC and JV 
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diameter (Table 1) and a lower JVD ratio on echocardiography. Patients with more severe 
mitral or tricuspid regurgitation also had higher RAP (Table 1 supplementary). However, 
there was no relation between RAP and sex, IHD, diabetes, hypertension or chronic 
obstructive pulmonary disease (COPD).  
 
Of patients with RAP <5 mmHg, 50% had a normal IVC (<16 mm), 10% had a JVD ratio <4 
(abnormal) and 17% had a dilated IVC (>20 mm) compared to 12%, 40% and 50% 
respectively of those with RAP >10 mmHg (Table 1).  
 
There was a positive correlation between RAP and age, left atrial volume index, systolic 
pulmonary pressure, IVC diameter, NTproBNP and JVD at rest and during deep inspiration 
(and decreasing JVD ratio). There was a negative correlation between RAP and haemoglobin 
and creatinine (Table 2). 
 
Of patients with RAP <5 mmHg, 79 (98%) had a clinically normal JVP and, conversely, of 
50 patients who were thought to have a clinically elevated JVP, only one had an RAP by 
NIRS of <5mmHg. However, 44 patients thought to have a clinically normal JVP had RAP 
>10 mmHg. Amongst patients with a clinically normal JVP, those who had a RAP >10 
mmHg had a higher plasma NTproBNP and lower haemoglobin, a larger LA and IVC 
diameter, and higher TR gradient (table 2 supplementary). 
 
Outcome   
During a median follow up of 595 (IQ range: 491 - 714) days, there were 49 primary 
outcomes amongst patients with HF of which 25 first events were HF hospitalisations and 24 
NIRS and outcome  Pellicori et al 130217_V2 
 
   Page 12 of 21 
 
were deaths. Overall, there were 27 deaths amongst patients with HF of which 70% were CV. 
There was one HF hospitalisation amongst the control group and no deaths. 
 
In univariable Cox regression analysis (Table 3), higher JVP assessed clinically, IVC by 
echocardiography, or RAP by NIRS, were associated with an increased risk of adverse 
outcome. In multivariable models, increasing log [NTproBNP] (Model A and B), albumin 
(Model B) and IVC diameter (Model C) were independently related to an adverse outcome, 
competing with RAP in the models (Table 4).  
 
Compared to patients with RAP <5 mmHg, those with RAP >10 mmHg measured by NIRS 
had a higher risk of an adverse outcome (HR: 2.38, 95% CI: 1.19-4.75, p=0.014, Figure 2). 
 
Compared to patients who had a low JVP both clinically and with NIRS (N= 79), those with 
low JVP clinically but high RAP with NIRS (N=44) had nearly a two-fold increase risk of 
death or admission with HF although this did not reach statistical difference (HR: 1.93, 95% 
CI 0.85-4.37; p=0.12), probably reflecting the low number of patients and events (figure 5 
supplementary). 
 
Discussion 
 
Measuring RAP with NIRS identifies out-patients with HF who have more signs of clinical, 
biochemical or echocardiographic congestion who are at greater risk of an adverse outcome. 
RAP measured by NIRS also identified patients with more severe congestion amongst those 
whose JVP was considered to be clinically normal.  
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A clinically raised JVP has high specificity in the assessment of volume overload but is 
insensitive. Moreover, inter-observer variability is substantial and dependent on experience and 
skills (16), the time and care taken to examine the patient, anatomical differences (particularly 
in the circumference of the neck) and swings in intra-thoracic pressure due to pulmonary 
disease. 
 
Although the art of physical examination remains the cornerstone of the evaluation of patients 
with HF (17), it often fails to detect subclinical congestion. In addition, clinical skills may be 
declining due to changes in training and the widespread availability and use of diagnostic 
imaging or biological tests (18). In an era dominated by the dilemma of treating increasing 
numbers of patients with chronic illnesses without a corresponding increase in resources, there 
is a growing trend to rely on nurses and less experienced doctors to assess and manage patients. 
Adding measurement of RAP using NIRS, to measurements of weight, heart rate and rhythm, 
and blood pressure done routinely by clinical assistants can easily be implemented even in a 
busy clinic. This could help identify patients with residual congestion and a worse prognosis 
who might benefit from adjustment in therapy. Using measurements of RAP to tailor diuretic 
dose for individual patients might merely be considered good clinical practice but, as with any 
new technology, it is important not to jump to conclusions but rather prove that preconceptions 
are correct.  
 
Assessing IVC or internal jugular venous diameter ultrasonically provides similar diagnostic 
and prognostic information to measurement of natriuretic peptides, and are valid alternatives 
to assess patients’ fluid status. Measurements of IVC diameter or internal JVD are objective, 
recordable and reproducible measures of congestion (5-8) that predict outcome.  
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However, such measurements require additional time, expertise and special probes. 
Moreover, although echocardiography might be done routinely when the patient is first 
referred, it will often not be repeated routinely at follow-up clinics. This might allow 
progression of the underlying disease to be missed. NIRS can also be measured in patients 
who are unable to cooperate with simple instructions, such as Valsalva or other respiratory 
manoeuvres, or in frail patients who may not tolerate long and detailed echocardiographic 
studies.  
  
Limitations 
The sample size is relatively small, and the number of events relatively few. Further, larger, 
multi-centre studies are required to confirm our findings. Although we found good 
correlations between RAP measured by NIRS and echocardiographic indices of congestion, 
we did not collect invasive haemodynamic data in our patients. However, others have shown 
that RAP measured by NIRS is accurate compared to invasive measurements (19).  
 
Although reproducibility was good, we found greater variability for lower RAP 
measurements, perhaps reflecting difficulties in identifying the jugular vein when RAP is not 
substantially raised. A potential source of error is the zero-reference placement which might 
lead to under- or overestimation of readings.  
 
We included a broad range of patients with cardiac dysfunction. Some patients will not have 
fulfilled enough criteria to be considered to have HF by some experts. However, this analysis 
was not designed as a diagnostic exercise but rather to investigate the range and significance 
of RAP measured by NIRS in a relevant population. A population of patients with narrowly 
defined HF might be considered to be of less interest. 
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Our control group consisted of many patients with or at high risk of CV disease already 
receiving ACE-inhibitors, beta-blockers and diuretics; it is possible that treatment had 
normalised circulating levels of NTproBNP and RAP. Thus, there is likely to be some 
overlap between patients in the disease and control groups in the present study. We believe 
that this is a strength, rather than a weakness, since it should be much easier to detect a 
difference if the control group had been fit, young, healthy individuals. One patient in the 
control group did subsequently have a HF related hospitalization but many more occurred in 
patients with HF even when RAP was <5 mmHg (similar to controls) (HR 7.59, 95% CI 
0.99-58.41, p=0.05). 
 
Conclusions 
Evaluation of RAP using NIRS identifies out-patients with heart failure who have a higher risk 
of an adverse outcome. This device might be used for the rapid bedside evaluation of right 
atrial pressure and congestion in patients with HF, especially when it cannot be assessed 
confidently by clinicians and measurement of natriuretic peptides are not immediately 
available. 
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Figure 1. Measurement of right atrial pressure (RAP) using Near-Infrared Spectroscopy 
(NIRS). With the patient reclining and head and neck elevated at 45°, the external jugular 
vein (JV) was identified and RAP measured using NIRS (Venus 1000, Mespere LifeSciences, 
Canada), a portable device that includes adhesive patches connected to a reading electrode 
placed over the external JV on the right side of the neck and a reference point aligned with 
the RA (the fourth intercostal space at the mid-antero-posterior diameter of the chest wall). 
Once stable waveforms and readings are obtained, the device records RAP (in mmHg) 
 
Figure 2. Kaplan Meier curve for the primary outcome of death from all causes and heart 
failure hospitalizations. Compared to those with normal RAP by NIRS (<5 mmHg, in red), 
HF patients with high RAP (>10 mmHg, in yellow) had more than a 2-fold higher risk of 
dying or being hospitalised for heart failure (HR: 2.38, 95% CI: 1.19-4.75, p=0.014). 
 
Figure 1, 2 and 3 supplementary: inter-operator reproducibility of RAP measurements by 
NIRS, and reproducibility by different intercostal spaces (3rd vs 4th and 4th vs 5th).    
 
Figure 4 supplementary: The distribution of RAP by NIRS in patients without (left panel) 
or with (right panel) heart failure (HF). 
 
Figure 5 supplementary: Kaplan-Meier (KM) curves for the primary composite endpoint 
(HF hospitalization or death) in patients with heart failure and ‘normal/low’ JVP both 
clinically and with NIRS (<5 mmHg; solid blue line), with HF and clinically ‘normal/low’ 
JVP (=0) but high RAP by NIRS (>10 mmHg; solid green line) and with HF and clinically 
raised JVP (>1) and RAP (>5 mmHg). Compared to those with ‘normal/low’ JVP (both 
clinically and with NIRS), those with clinically ‘normal/low’ JVP but raised RAP by NIRS 
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had around a 2-fold increase in the risk of an adverse outcome, although the difference did 
not reach statistically significance. Those with clinically high JVP and high RAP by NIRS 
had the worst outcome.  
 
 
 
